GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » EPS (Diluted)

Actelion (XSWX:ATLNE) EPS (Diluted) : CHF0.00 (TTM As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion EPS (Diluted)?

Actelion's Earnings per Share (Diluted) for the three months ended in Mar. 2017 was CHF0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 was CHF0.00.

Actelion's EPS (Basic) for the three months ended in Mar. 2017 was CHF0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2017 was CHF0.00.

Actelion's EPS without NRI for the three months ended in Mar. 2017 was CHF0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2017 was CHF0.00.

During the past 12 months, Actelion's average EPS without NRIGrowth Rate was 29.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 18.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Actelion's highest 3-Year average EPS without NRI Growth Rate was 123.50% per year. The lowest was 0.50% per year. And the median was 35.90% per year.


Actelion EPS (Diluted) Historical Data

The historical data trend for Actelion's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion EPS (Diluted) Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.57 - - - -

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Actelion's EPS (Diluted)

For the Biotechnology subindustry, Actelion's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's PE Ratio distribution charts can be found below:

* The bar in red indicates where Actelion's PE Ratio falls into.



Actelion EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Actelion's Diluted EPS for the fiscal year that ended in Dec. 2016 is calculated as

Diluted EPS (A: Dec. 2016 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(696.386-0)/118.120
=5.90

Actelion's Diluted EPS for the quarter that ended in Mar. 2017 is calculated as

Diluted EPS (Q: Mar. 2017 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(196.957-0)/115.457
=1.71

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (XSWX:ATLNE) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Actelion EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Actelion's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines